By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BioAlliance Pharma 

59, Boulevard du Général Valin

Paris    75015  France
Phone: 33-0-145-5876-00 Fax: 33-0-145-5808-81


Company News
BioAlliance Pharma: Approval Of Onxeo’s Admission To Secondary Listing And Trading On NASDAQ OMX Copenhagen 7/24/2014 10:45:18 AM
BioAlliance Pharma Announces The Launch Of Sitavig® In The United States By Its Partner Innocutis 7/21/2014 12:28:33 PM
BioAlliance Pharma Strengthens Its Financial Resources With The Support Of Its Top Shareholder 7/18/2014 11:10:01 AM
BioAlliance Pharma And TopoTarget A/S Shareholders Approve Proposed Cross-Border Merger To Create Onxeo 6/30/2014 10:42:09 AM
BioAlliance Pharma Release: Execution Of A License Agreement With EMS For Sitavig® In Brazil 6/25/2014 10:41:54 AM
BioAlliance Pharma Has Received Pre-Approval For The Secondary Listing Of The Shares Of The Merged Company On NASDAQ OMX Copenhagen 6/20/2014 11:10:24 AM
BioAlliance Pharma, TopoTarget A/S To Merge, Combined Entity To Be Named Onxeo 5/22/2014 8:50:36 AM
BioAlliance Pharma: Livatag® Receives Fast Track Designation From The FDA For The Treatment Of Primary Liver Cancer 5/20/2014 8:43:07 AM
BioAlliance Pharma SA: Quarterly Information As Of March 31, 2014 5/1/2014 2:38:37 PM
BioAlliance Pharma Release: Quarterly Information As Of March 31, 2014 4/30/2014 12:53:40 PM